Blue Shield Of California’s Pharmacy Benefit Overhaul Could Still See Boost From Transparency Legislation
The payor’s multiyear plan to ditch the traditional PBM model and use multiple vendors has drawn a lot of skepticism from other actors in the health care system, but Blue Shield is hoping that it can help give policymakers some momentum, VP Lum tells the Pink Sheet.
You may also be interested in...
As Hatch-Waxman celebrates its 40th anniversary, the chair of the US generic trade association talks about striking the right balance on supply and pricing, preventing shortages, and improving Medicare price negotiations.
Easy House passage of a health package that includes PBM reforms and policies to help generic drug makers likely creates enough momentum to spur bicameral action. Overall policy still a work in progress – presenting last-minute opportunities for other drug pricing reforms to get tacked on.
Offering a regulatory Mt. Rushmore to place the outgoing principal deputy commissioner in historical context.